Wealth Enhancement Advisory Services
RYTM icon

Wealth Enhancement Advisory Services’s Rhythm Pharmaceuticals RYTM Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,885
Closed -$204K – 4409
2026
Q2 		$204K Buy
+1,885
New +$170K ﹤0.01% 3570

Other funds holding RYTM

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Capricorn Fund Managers
Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
iA Global Asset Management
iA Global Asset Management Quebec, Quebec, Canada $8.54B AUM 39.73% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Wealth Enhancement Advisory Services's RYTM Position: Q3 2026 in Review

Wealth Enhancement Advisory Services sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2026, closing a stake of 1,885 shares — an estimated $204K sold.

Wealth Enhancement Advisory Services first reported a position in RYTM in Q2 2026 and held it in 1 quarter. The position peaked at $204K in Q2 2026. 83 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • Wealth Enhancement Advisory Services reported no remaining Rhythm Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 1,885 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $204K.
  • Wealth Enhancement Advisory Services first reported a position in Rhythm Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Wealth Enhancement Advisory Services's Rhythm Pharmaceuticals position peaked at $204K in Q2 2026.
  • 83 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.